Stoke Therapeutics - STOK Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Stoke Therapeutics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" STOK shares.
View STOK analyst ratings or view top-rated stocks.

5 brokerages have issued twelve-month price objectives for Stoke Therapeutics' stock. Their STOK share price forecasts range from $38.00 to $50.00. On average, they expect the company's share price to reach $44.83 in the next twelve months. This suggests a possible upside of 245.1% from the stock's current price.
View analysts price targets for STOK or view top-rated stocks among Wall Street analysts.

Stoke Therapeutics' stock was trading at $23.99 at the beginning of the year. Since then, STOK shares have decreased by 45.9% and is now trading at $12.99.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our STOK earnings forecast.

Stoke Therapeutics, Inc. (NASDAQ:STOK) released its quarterly earnings data on Monday, August, 8th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.70) by $0.07. The business had revenue of $3.23 million for the quarter, compared to the consensus estimate of $2.71 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Stoke Therapeutics investors own include Gossamer Bio (GOSS), Editas Medicine (EDIT), Alector (ALEC), LogicBio Therapeutics (LOGC), NVIDIA (NVDA), Precision BioSciences (DTIL), Kaleido Biosciences (KLDO), Homology Medicines (FIXX), Marvell Technology (MRVL) and Invitae (NVTA).

(STOK) raised $100 million in an initial public offering on Wednesday, June 19th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Credit Suisse acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

Stoke Therapeutics trades on the NASDAQ under the ticker symbol "STOK."

Stoke Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include FMR LLC (7.52%), Cowen AND Company LLC (3.86%), Bank of Montreal Can (2.57%), Millennium Management LLC (2.41%), Healthcare of Ontario Pension Plan Trust Fund (2.31%) and Deutsche Bank AG (2.00%). Insiders that own company stock include Apple Tree Partners Iv, LP, Arthur Tzianabos, Barry Ticho, Edward M Md Kaye, Gene Liau, Huw M Nash, Huw M Nash, Robin A Walker, Rtw Investments, Lp and Stephen J Tulipano.
View institutional ownership trends.

Shares of STOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of STOK stock can currently be purchased for approximately $12.99.

Stoke Therapeutics (NASDAQ:STOK) has a market capitalization of $512.05 million. The company earns $-85,810,000.00 in net income (profit) each year or ($2.56) on an earnings per share basis.

The company employs 102 workers across the globe.

Stoke Therapeutics' mailing address is 45 WIGGINS AVENUE, BEDFORD MA, 01730. The official website for the company is www.stoketherapeutics.com. The company can be reached via phone at (781) 430-8200 or via email at ir@stoketherapeutics.com.